Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) - Total Liabilities
Based on the latest financial reports, Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (600332) has total liabilities worth CN¥47.87 Billion CNY (≈ $7.00 Billion USD) as of March 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd - Total Liabilities Trend (1997–2025)
This chart illustrates how Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's total liabilities have evolved over time, based on quarterly financial data. Explore 600332 strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Competitors by Total Liabilities
The table below lists competitors of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Jiangsu Hoperun Software Co Ltd
SHE:300339
|
China | CN¥2.28 Billion |
|
Shanghai Friendess Electronics Tech
SHG:688188
|
China | CN¥383.40 Million |
|
Waystar Holding Corp. Common Stock
NASDAQ:WAY
|
USA | $1.90 Billion |
|
Millrose Properties, Inc.
NYSE:MRP
|
USA | $3.72 Billion |
|
Sinopec Oilfield Service Corp
SHG:600871
|
China | CN¥66.96 Billion |
|
Global Power Synergy PCL
BK:GPSC
|
Thailand | ฿147.82 Billion |
|
X-Energy, Inc. Class A Common Stock
NASDAQ:XE
|
USA | $150.08 Million |
|
Shenzhen Energy Group Co Ltd
SHE:000027
|
China | CN¥106.50 Billion |
Liability Composition Analysis (1997–2025)
This chart breaks down Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see Guangzhou Baiyunshan Pharmaceutical Hold (600332) total assets.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.60 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 1.21 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.53 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd (1997–2025)
The table below shows the annual total liabilities of Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd from 1997 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | CN¥43.39 Billion ≈ $6.35 Billion |
-1.20% |
| 2024-12-31 | CN¥43.91 Billion ≈ $6.43 Billion |
+4.78% |
| 2023-12-31 | CN¥41.91 Billion ≈ $6.13 Billion |
+2.15% |
| 2022-12-31 | CN¥41.03 Billion ≈ $6.00 Billion |
+17.93% |
| 2021-12-31 | CN¥34.79 Billion ≈ $5.09 Billion |
+10.26% |
| 2020-12-31 | CN¥31.55 Billion ≈ $4.62 Billion |
+2.11% |
| 2019-12-31 | CN¥30.90 Billion ≈ $4.52 Billion |
+9.05% |
| 2018-12-31 | CN¥28.34 Billion ≈ $4.15 Billion |
+213.08% |
| 2017-12-31 | CN¥9.05 Billion ≈ $1.32 Billion |
+9.80% |
| 2016-12-31 | CN¥8.24 Billion ≈ $1.21 Billion |
+14.70% |
| 2015-12-31 | CN¥7.19 Billion ≈ $1.05 Billion |
+14.95% |
| 2014-12-31 | CN¥6.25 Billion ≈ $914.84 Million |
+19.61% |
| 2013-12-31 | CN¥5.23 Billion ≈ $764.86 Million |
+159.91% |
| 2012-12-31 | CN¥2.01 Billion ≈ $294.28 Million |
+110.34% |
| 2011-12-31 | CN¥956.09 Million ≈ $139.91 Million |
+14.50% |
| 2010-12-31 | CN¥835.05 Million ≈ $122.19 Million |
+1.72% |
| 2009-12-31 | CN¥820.92 Million ≈ $120.13 Million |
-9.39% |
| 2008-12-31 | CN¥905.99 Million ≈ $132.58 Million |
-68.90% |
| 2007-12-31 | CN¥2.91 Billion ≈ $426.22 Million |
+18.63% |
| 2006-12-31 | CN¥2.46 Billion ≈ $359.28 Million |
+7.16% |
| 2005-12-31 | CN¥2.29 Billion ≈ $335.27 Million |
-10.02% |
| 2004-12-31 | CN¥2.55 Billion ≈ $372.62 Million |
+20.63% |
| 2003-12-31 | CN¥2.11 Billion ≈ $308.88 Million |
+20.60% |
| 2002-12-31 | CN¥1.75 Billion ≈ $256.13 Million |
+23.83% |
| 2001-12-31 | CN¥1.41 Billion ≈ $206.85 Million |
-9.71% |
| 2000-12-31 | CN¥1.57 Billion ≈ $229.10 Million |
+2.80% |
| 1999-12-31 | CN¥1.52 Billion ≈ $222.87 Million |
-4.66% |
| 1998-12-31 | CN¥1.60 Billion ≈ $233.77 Million |
-6.08% |
| 1997-12-31 | CN¥1.70 Billion ≈ $248.91 Million |
-- |
About Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited engages in the pharmaceutical and healthcare industry in the People's Republic of China and internationally. The company operates through Modern Chinese Medicine Business, Chemical Pharmaceutical Technology Business, Natural Beverage Business, Pharmaceutical Commercial Business, and Other segments. It is involved in the research, develo… Read more